You are here

tergenpumatucel-L

Two Diversified Biotechs to Watch After Impressive ASCO Data

Motley Fool

Mon, 06/3/13 - 12:36 pm

ONYX Pharmaceuticals

tergenpumatucel-L

NewLink Genetics

NewLink Genetics Presents Positive Phase 2 Data on Novel Immunotherapy, Tergenpumatucel-L, in Non-Small Cell Lung Cancer at the ASCO 2013 Annual Meeting

Yahoo/PR Newswire

Sat, 06/1/13 - 12:19 pm

NewLink Genetics

tergenpumatucel-L

non-small cell lung cancer